#### Zosano Pharma Corp Form 3 June 24, 2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549 OMB Number:

### **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

## OMB APPROVAL

3235-0104 January 31, Expires: 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> KELLERMAN DONALD J	<ul><li>2. Date of Event Requiring</li><li>Statement</li><li>(Month/Day/Year)</li></ul>	<sup>g</sup> 3. Issuer Name <b>and</b> Ticker or Trading Symbol Zosano Pharma Corp [ZSAN]				
(Last) (First) (Middle)	06/15/2016	4. Relationship of Reporting Person(s) to Issuer		5. If Amendment, Date Original Filed(Month/Day/Year)		
C/O ZOSANO PHARMA CORPORATION, 34970 ARDENTECH COURT (Street) FREMONT, CA 94555		Director X Officer (give title below	all applicable) 10% ( Other r) (specify belo Dev & Med Af	w)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person	
(City) (State) (Zip)	Table I - N	Non-Derivati	ive Securiti	es Bei	neficially Owned	
1.Title of Security (Instr. 4)	2. Amount of Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nat Owner (Instr.		
Reminder: Report on a separate line for ea owned directly or indirectly.	ach class of securities benefici	ially SI	EC 1473 (7-02)	)		

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)			3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	Derivative Security	Security: Direct (D)	

### Edgar Filing: Zosano Pharma Corp - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Employee Stock Option (right to buy)	(1)	12/15/2025	Common Stock	30,000	\$ 2.26	D	Â
Employee Stock Option (right to buy)	(2)	03/29/2026	Common Stock	12,000	\$ 2.57	D	Â

# **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationships					
i o	1		10% Owner	Officer	Other		
KELLERMAN DONALD J C/O ZOSANO PHARMA CORPORATION 34970 ARDENTECH COURT FREMONT, CA 94555		Â	Â	VP, Clinical Dev & Med Affairs	Â		
Signatures	6						
/s/ Donald Kellerman	06/24/2016						
<u>**</u> Signature of Reporting Person	Date						

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the total number of shares underlying the stock option vest on December 15, 2016, and the remaining underlying shares vest in equal monthly installments over the following three-year period.
- (2) 25% of the total number of shares underlying the stock option vest on March 29, 2017, and the remaining underlying shares vest in equal monthly installments over the following three-year period.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.